Sage Journals: Discover world-class research

Abstract

The innate immune system of the brain is mainly composed of microglial cells, which play a key role in the maintenance of synapses and the protection of neurons against noxious agents or lesions owing to their phagocytic activity. In the healthy brain, microglia are highly motile and strongly interact with neurons either by physical contact, induction of oxidative stress or through specific mediators, such as chemokines and cytokines. In response to inflammatory insult however, microglial cells get activated and produce inflammatory cytokines. The action of cytokines on specific receptors expressed in the brain triggers the development of sickness behavior and altered cognitive and emotional processes. The effects are acute and reversible as normal behavior is restored once the synthesis of inflammatory brain cytokines returns to baseline after a few hours. However, in pathological situations, these cytokines may reach toxic levels and have irreversible consequences such as neuronal death, as observed in neurodegenerative disorders such as Alzheimer's disease. Omega-3 (n-3) polyunsaturated fatty acids (PUFAs) are essential nutrients and fundamental components of neuronal and glial cell membranes. They accumulate in the brain during the perinatal period in a dietary supply-dependent fashion. Their brain levels may diminish with age, but can be increased by diets enriched in n-3 PUFAs. Changes in the immune profile have been associated with n-3 PUFAs intake in humans and animal models. Therefore, the increasing exposure of the population to diets low in n-3 PUFAs could contribute to the deleterious effects of the chronic activation of microglia in the brain.

Keywords

Docosahexaenoic acid microglia cytokine brain aging Alzheimer disease memory

1 Introduction

The central nervous system (CNS) has long been considered as an immunoprivileged organ. Indeed, in physiological conditions, the blood brain barrier (BBB), owing to its tight junctions, considerably restricts the entry of immune cells, notably lymphocytes, into the brain. Research in neuroimmunology has shown that the brain possesses its own line of defense, activated by immune stimuli, and closely linked to the peripheral immune system. Although not as isolated as first thought, there are important distinctions between the peripheral and the central immune systems. Inflammatory cytokines, which are important mediators of the communication within the immune system, also act in the brain where they can activate microglial cells and astrocytes that in turn, can produce cytokines, chemokines, complement proteins and nitric oxide [1 –3]. In physiological conditions, the synthesis of brain immune mediators is finely regulated, allowing a rapid return to basal levels, without leading either to BBB failure or cerebral lesion. However, when synthesized in large amounts or in a chronic fashion, these factors may have toxic effects on neurons, resulting in substantial neuronal dysfunction that can lead to cell death [4 –7]. During aging, chronic microglial reactivity and production of low levels of inflammatory cytokines occurs and can produce alterations of neuronal functions [8]. Indeed, this age-associated inflammation, characterized by the increased production of brain cytokines, increases the vulnerability of the aging brain to immune stimuli, and the risk of developing delirium and/or neurodegenerative disorders with an inflammatory component, such as Alzheimer's disease (AD) [9 –11]. Accordingly, clinical and epidemiological studies have suggested a possible association between the systemic expression levels of inflammatory cytokines and the incidence of functional/behavioral alterations (cognitive or mood disorders) in psychiatric and elderly subjects [12 –15]. In this context, limiting the development of chronic neuroinflammation could protect the brain against neurodegenerative disorders. This could be achieved with the diet, a modifiable environmental factor to which each individual is exposed throughout his life.

Increasing attention has been paid to omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acids (PUFAs). These micronutrients are essential since their precursors cannot be synthesized de novo by the organism. Moreover, their synthesis is extremely limited in most mammals (less than 5% of the precursors are converted) [16]. Increasing data in animal models as well as in humans suggest that dietary PUFA exert immunomodulatory effects [17 –20]. Indeed, n-3 long chain PUFAs form the basis of lipid derivatives (neuroprotectins and resolvins) with anti-inflammatory properties [21 –26]. Moreover, they are precursors of eicosanoids including leukotrienes, prostaglandins and thromboxanes, which are important modulators of the inflammatory response. However, they have lower biological potency than eicosanoids derived from n-6 PUFAs such as arachidonic acid [27, 28]. The brain is extremely rich in PUFAs, and the accumulation of PUFAs in brain tissues first takes place during the perinatal period in proportions which are dependent on maternal dietary levels [29, 30]. Conversely, the levels of brain PUFA has been reported to diminish with aging, although this decrease can be prevented or corrected by appropriate nutritional strategies [31]. Since the Industrial Revolution, we have observed a decrease in energy expenditure related mainly to sedentary lifestyle combined with an increase in the consumption of high energy foods characterized by elevated levels of sugar, saturated fats, and n-6 PUFAs, poor in n-3 PUFAs, vitamins, proteins and micronutriments [32, 33]. The resulting imbalance in the n-6:n-3 ratio from this dramatic modification in the dietary intake is currently estimated to 10:1 to 20:1 in Western diets, whereas the current recommended ratio is 1:1 to 2:1 [32, 33]. With the known immunomodulation resulting from n-3 PUFAs intake, this imbalance could therefore contribute to prime the brain to the deleterious effects of inflammatory cytokines, and eventually to the development of neurodegenerative and/or neurobehavioral disorders.

2 The brain innate immune system (BIIS)

In the periphery, tissue injuries caused by trauma or pathogens induce a rapid local inflammatory response involving local cells and characterized by the synthesis and release of proinflammatory factors, among which cytokines and chemokines, followed by systemic recruitment of immune cells. The purpose of this local response is to eliminate pathogens and to promote tissue repair. However, the failure of resolving the insult and dysregulated injury may lead to chronic inflammation, which is toxic for the tissue, ultimately resulting in cell death. In addition, peripheral inflammation can also influence brain immunity [1]. However, it appears that the steps involved in the cerebral immune response are distinct from those of the periphery. Therefore, the term “neuroinflammation” is broadly used to discriminate the brain from the peripheral inflammation. “Neuroinflammation” describes the brain inflammatory response involving not only peripheral immune cells influx into the brain but also the specialized response of brain innate immune system (BIIS) [34].

Microglial cells are the main cells of the BIIS. They are the parenchymal resident macrophages of the brain where they act as a first line of defense(phagocytosis, antigen presentation, cell recruitment and secretion of cytokines) [35, 36]. They account for 5 to 20% of the non-neuronal glial cells, depending on the brain structures analyzed. Microglia are distinct from the brain macrophages found in the meninges, choroid plexus, and perivascular space, owing to their different developmental origin. Indeed, recent data highlight that microglia derives from macrophages produced by primitive hematopoiesis in the yolk sac [37 –40] while brain macrophages derive from myeloid precursor in the bone marrow [41, 42]. Microglia precursors colonize the CNS during the embryonic and fetal phases of development [43]. Interestingly, an increase of CD11b+/F4/80+ microglia occurs in the post-natal brain of rodents [37]. However, recent evidence suggests that this increase in microglial cell number is not induced by the recruitment of blood-derived myeloid precursors but instead results from the proliferation of resident microglial cells [39, 44]. Recent studies provide new insights into the development of the microglial population from yolk sac progenitors during embryogenesis. In contrast with macrophages from other tissues, microglia persist throughout the entire life of an individual [42]. There is a growing interest to characterize microglia cells profile and signature. Very recent data reveals that microglia express a decreased number of mRNA types as compared to tissue macrophages [45] and display a specific mRNA signature that is dependent on TGFβ [46].

Microglia are particularly sensitive to changes in their microenvironment and readily become activated in response to infection, trauma or disease [47]. In healthy brain, the microglia can phagocyte apoptotic neurons and debris and reduce neuroinflammation which, in turn is beneficial to viable neurons [48]. However, in inflammatory or pathologic situations, the phagocytic adaptor protein MFG-E8 is released by microglia and binds to phosphatidylserine (PS) exposed on apoptotic neurons. This activates neuronal phagocytosis by microglia via the vitronectin receptor [49]. Annexin A1, another eat-me signal released by microglia, serves as a bridge with PS on dying neuron, helping the microglia to discriminate between apoptotic neurons and healthy neurons [50]. Recently, new data revealed that activated microglia in inflammatory state appears to lose their ability to discriminate between apoptotic and viable neurons, resulting in phagocytosis of diseased as well as healthy neurons [51].

In the adult brain, microglial cells have a ramified morphology when quiescent, and ameboid morphology when activated. Ramified microglia generally display less phagocytic activity and weakly express ligands and receptors involved in macrophage function. Disseminated throughout the brain parenchyma, they use their processes to receive signals such as danger-associated molecular patterns (DAMP) and pathogen-associated molecular patterns (PAMP) from their microenvironment, which reveal the existence of an endogenous pathological signal or the presence of a pathogen, respectively. In order to do this, microglial cells express a set of pattern recognition receptors (PRRs) including the Toll-like receptors (TLRs) that allow the recognition of PAMPs, such as the bacterial endotoxin [52, 53], and DAMPS, such as misfolded proteins [54], and promote brain inflammatory reaction [55]. The activation of PRRs by PAMPS and DAMPs induces a signaling cascade leading to the secretion of cytokines and chemokines. The microglial cells further coordinate the inflammatory response via the expression of membrane receptors for inflammatory cytokines interleukin (IL)-1β, tumor necrosis factor (TNF)α and IL-6 and several chemokines. In vivo, IL-1β, TNFα and IL-6 are produced by microglia in response to peripheral immune stimuli such as bacterial endotoxin lipopolysaccharide (LPS) [56].

The BIIS response promotes clearance of pathogens, toxic cellular debris and apoptotic cells and therefore protects the brain. Indeed, a selective ablation of proliferating microglia exacerbates brain damage in adult and in neonatal hypoxic ischemic injury models [57]. However, under some circumstances, the sustained expression of inflammatory factors such as cytokines can lead to neurodegeneration [7, 58]. The BIIS response is therefore a double-edged sword depending on a fine balance between protective and detrimental effects that needs to be tightly controlled. Real-time in vivo imaging technology has revealed that both in health and disease, microglia exist in an active state but their role in the brain depends on the broad phenotype spectrum they can adopt [59]. Microglia phenotypes, so called polarization, could be crucial in the protective or detrimental role of PRR-activated BIIS response toward neurons. According to what was described for macrophages, it has been suggested that activated M1 cells have cytotoxic properties, M2a are involved in repair and regeneration, M2b promote immunomodulation, while M2c have an acquired-deactivating phenotype [60] (Fig. 1). In vivo, microglia express proinflammatory cytokines associated with a M1 phenotype (IL-1, IL-6, IL-12 and TNFα) in response to an immune stimulus. Recent evidence indicates that neurons exert some control on microglia activity [61]. The extent of neuroinflammation therefore depends on the bi-directional interactions between neurons and microglia. Recruitment and activation of microglial cells require well-organized reciprocal communication between these two cell types [36, 62]. As a result, neurons release ON or OFF signals to regulate the activation of microglia. On the one hand, OFF signals (CD200, CX3CL1, CD47, CD55 and HMGB1) are produced by healthy neurons to keep microglia in their surveillance mode. On the other hand, damaged neurons express inducible ON signals (chemokines, purine and glutamate) to activate microglia and phagocytosis [36]. Interestingly, such neuron-glia interaction is impaired in the aged brain leading to amplified and prolonged microglial activation and production of proinflammatory cytokines [63, 64].

Fig. 1

Microglia phenotype plasticity. Microglia can adopt different phenotypes: M1 (classical activation), M2a (alternative activation), M2b (immunoregulatory) and M2c (acquired-deactivation). According to their phenotype, microglia cells express different clusters of differentiation (CD) such as CD86 or CD206, or type-II proteins of major histocompatibility complex (MHC) and secrete different cytokines and chemokines. CCL: chemokine (C-C motif) ligand; IFN: interferon; IL: interleukine; LPS: lipopolysaccharide; TGF: transforming growth factor; TNF: tumor necrosis factor; Ym1: YKL-40, chitinase 3-like 3.

3 Biis in the Aging Brain and Neurodegenerative Diseases

3.1 Neuroinflammation, the aged brain and Alzheimer's disease

Aging is associated with senescence of microglia, impaired microglia phagocytic activity and low-grade neuroinflammation [65], which is characterized by a higher expression of proinflammatory cytokines IL-1β, IL-6 and TNFα to the detriment of anti-inflammatory factors such as IL-10 and IL-4. This state is called inflammaging at the periphery and in the brain [66]. The overproduction of proinflammatory cytokines in the absence of infection or injury in the aged brain could be linked to the impairment of microglial activity. Indeed, microglia number and activity increases during normal aging [67]. These aged cells, in addition to producing proinflammatory cytokines, contain lipofuscine granules, and decreased processes complexity, a morphological change found in activated microglia [47, 68]. In addition, microglia in the aged brain express higher levels of CD86, major histocompatibility complex II (MHC II), TLR and CR3/CD11b which are markers of activation [69, 70]. Senescent microglia display reduced phagocytic activities of beta-amyloid in aged transgenic mice which could be due to their M1 phenotype [71]. Mechanisms involved in increased microglia activation in the aged brain are not fully understood, however as CD200 and CX3CR1 expression is impaired it could be that neuron-glia interactions are disturbed [67, 72].

The involvement of microglia in the communication of systemic inflammatory signals to neurons has been recently reviewed [73]. One of the most important new knowledge is that microglia become more susceptible to inflammatory stimuli when they are primed by pathological insults contributing to the progression of neurodegenerative diseases such as Alzheimer's Disease (AD) [73, 74]. The characteristics of primed microglia remain to be determined. However, increased number of microglia, together with changes in morphology and increased expression of cell surface antigens such as CD68, complement receptors (CR3) and/or MHC have been consistently reported in priming context as first reported in prion disease [75]. Priming phenomenon has been observed in aging [76], after the administration of proinflammatory endotoxins [77, 78] and in animal models of AD and Parkinson disease [7, 79]. Interestingly, aging microglia express a specific sensome (defined as proteins sensing microbes) that could confer them a higher vulnerability to inflammatory stimuli [70]. Indeed, the concept of microglia priming provides new view of how systemic inflammation could contribute to the progression of neurodegenerative diseases, through increased production of inflammatory cytokines that could damage neurons and/or loss of neuroprotective properties.

The first evidence of an inflammatory response in AD comes from case-control studies showing immune anomalies in blood or CSF from living individuals or cerebral tissue collected post-mortem. For example, plasma cytokine profiles, key components of the complement system and immune cells are altered early in the disease [80 –83]. High levels of pro and anti-inflammatory factors, and increased PRR and chemokines expression are found in the brain of AD patients [4, 84]. Activated microglia in the brain of AD patients have been detected by (R)-[³H]PK11195 PET binding to peripheral benzodiazepine receptors [85]. A second set of evidence comes from epidemiology. Indeed, chronic non-steroidal anti-inflammatory drugs (NSAID) use has been associated to lower risk of AD [86, 87]. Finally, data generated in animal models suggest a causal link between brain amyloid or tau pathologies and the triggering of an immune response [5 , 89], although this view is also disputed [90]. In transgenic APP/PS1 or 3xTg-AD mice, reports suggest that microglia activation starts between 6 and 12 months, as assessed with CD45, Iba1 and/or F4/80 IHC [91 –94]. Therefore, despite conflicting data, it appears clear that changes in parameters involved in central or peripheral inflammation are associated with AD.

However, the role of inflammation or the immune system in AD pathogenesis is still a matter of debate as both beneficial and adverse effects of inflammation have been reported [95 –101]. Recent data highlighted that microglia, because of its impaired activity in the AD brain, cannot phagocytocize Aβ that therefore accumulates [102, 103]. In turn, Aβ accumulation activates microglia in a chronic proinflammatory state that contributes to the disease progression and, ultimately cognitive decline [4]. Higher levels of IL-1 have been implicated in both the initiation and progression of neuropathological changes [104]. Accordingly, overexpression of IL-1 in the AD brain has been linked to an increased microglial activity, frequently associated with amyloid plaques [105]. In addition, brain from Tg2576 mice (a model of AD) exhibits significant increases in IL-1 expression in comparison to healthy animals [106]. Overexpresssion of IL-1β in the 3xTg-AD mouse model of AD suggest that amyloid and tau pathology are differentially regulated, with a reduction in amyloid deposit but an exacerbation of Tau hyperphosphorylation [107]. Such effects could involve the fractalkine pathway as the expression of its receptor CX3CR1 have been reported to be associated with either a decrease [108] or an activation of Aβ clearance [109 –112] and increase Tau phosphorylation [113]. Therefore, further studies are needed to precise the role of the fractalkine pathway in these processes.Globally, a crucial issue that remains unclear is whether the immune response observed in AD is a compensatory mechanism with a neuroprotective effect, part of a vicious circle leading to neuronal death and cognitive decline, or both [72 , 115]. Answers to this question will determine how neuroinflammation can be “tamed” for the purpose of developing therapeutic interventions.

In the last decades, trials aiming at modulating brain inflammation in AD patients have been dis- appointing [72 , 116–118]. This included assays with NSAID, steroid anti-inflammatory (prednisone) or with immunomodulators such as TNF antagonists and polyclonal or monoclonal immunoglobulins [72 , 119]. However, consistent with epidemiology data [86], it remains likely that the modulation of inflammation is more suitable for a preventive intervention [120]. Unfortunately, no such preventive study has been completed yet, the ADAPT study on COX-1 and COX-2 inhibitors having been ended abruptly due to unsuspected side effects [72, 121]. Nevertheless, further data analysis from the ADAPT study do not provide a clear answer to the hypothesis that celecoxib or naproxen exert a preventive action against AD [122, 123]. Because the role of BIIS in the development of AD is complex, other strategies aiming at optimizing microglia activity, rather than just blocking inflammatory factors synthesis in the brain could be more beneficial [4, 72].

4 Polyunsaturated fatty acids and neuroinflammation

4.1 N-3 PUFAs: A brief overview

PUFAs of the n-3 or n-6 families are essential nutrients, as the precursors of these two series (linoleic acid (18:2n-6, LA) and α-linolenic acid (18:3n-3, ALA)) cannot be generated de novo in mammals, they have to be provided by the diet. They are respectively metabolized by a series of elongation and desaturation steps into arachidonic acid (20:4 n-6, AA) and eicosapentaenoic acid (20:5 n-3, EPA) and docosahexaenoic acid (22:6 n-3, DHA) (Fig. 2). These long chain PUFAs are incorporated into cell membranes as phospholipids. The liver is the main site of conversion of LA and ALA into long chain PUFAs, although other organs such as the brain also express the necessary elongases and desaturases [124]. Since the two series of PUFAs compete for the use of the enzymes necessary for their biosynthesis, and because the conversion into long chain is extremely limited (less than 5% of the precursors is converted), their supply by the diet is of particular importance. Foods that were previously consumed by humans were obtained from hunting and fishing and were relatively rich in n-3 long chain PUFAs. Since the Industrial Revolution, the ratio of n-6:n-3 PUFAs in the diet has increased from 1 to almost 20 in industrialized countries like the United States, leading to a suboptimal dietary consumption of n-3 PUFAs [33, 125].

Fig. 2

Elongation and desaturation of n-6 and n-3 PUFA and pathways in active eicosanoid metabolism from arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid. n-6 and n-3 essential fatty acids precursors are linoleic acid (LA) and α-linolenic acid (ALA). These precursors are metabolized into arachidonic acid (AA) and eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) respectively. AA is metabolized into derivatives that belong to the eicosanoid family, series 2 and 4. EPA and DHA metabolic derivatives belong to the eicosanoid family, series 3 and 5, resolving family (series D and E) and neuroprotectins. Tx: thromboxane; PG: prostaglandines; COX-2: cycloxygenase 2; LT: leukotrienes; LOX: lipoxygenase; Lx: lipoxin; NPD1: neuroprotectin D1.

The dietary deficiency in n-3 PUFAs is associated with a significant decrease in DHA in the brain, and could thus promote neuroinflammatory processes and the subsequent development of inflammation-related CNS disorders [8]. However, the effect of n-3 long chain PUFA supplementation to generate a favorable inflammatory marker profile is currently subject to debate. In populations with a high n-3 long chain PUFA dietary intake due to elevated fish consumption, such as Greenland Inuits, the incidence of ischemic heart and autoimmune diseases (such as psoriasis, asthma or multiple sclerosis) is low [126, 127], but inflammatory markers such as YKL-40 and hsCRP are rather found to be increased [128]. While some clinical studies have reported anti-inflammatory effects of n-3 long chain PUFAs administered in the context of chronic and autoimmune inflammatory disorders, other reports fail to reproduce these findings (for review [28]).

4.2 N-3 PUFAs and inflammatory mechanisms

Attenuation of the inflammatory response is one of the most frequently cited mechanisms of action of n-3 PUFAs, despite limited convincing evidence of such an action in cerebral tissues until recently [129]. As stated above, a high n-3 PUFA intake decreases AA content and at the same time, increases DHA in the brain. Since n-3 PUFAs compete with AA as substrates for cyclooxygenase (COX) and lipoxygenases (LOX), increased n-3 PUFA concentration is expected to reduce the production of the more potent inflammatory eicosanoids derived from AA [25 , 130–132]. Therefore, food rich in n-3 PUFA such as fish or walnut have been found to limit the inflammatory response in preclinical studies [133 –136].

More specifically, n-3 PUFAs also decrease the production of various important inflammatory cytokines such as TNFα, IL-1, and IL-6 [20 , 137]. Indeed, DHA decreases the expression of brain inflammatory markers following systemic LPS administration [138], brain ischemia-reperfusion [20, 139] and spinal cord injury [140]. However it remains difficult to gauge the direct effect of DHA on BIIS, since the primary CNS injury is also attenuated in these studies. High-fat intake in n-3 PUFA-deprived animals induces a rise of GFAP, a marker of astrogliosis, in mouse brains [141]. Recently, we have demonstrated thatin vitro, in murine microglia induced by LPS, the production of IL-1β and TNFα by is strongly inhibited by DHA through its effect on LPS signaling pathway nuclear factor-κB [137]. In vivo, chronic dietary n-3 PUFA deficiency significantly increases the production and release of IL-6 and TNFα in the blood [142]. In addition, mice exposed throughout life to a diet devoid of n-3 PUFAs display lower brain DHA and higher LPS-induced IL-6 levels in the plasma and the hippocampus [138]. In parallel, n-3 PUFAs have been shown to decrease the levels of COX-2 in vitro [143] and in vivo [20, 144].

The recent discovery of a novel family of endogenously generated autacoids, namely resolvins and protectins, with potent anti-inflammatory and proresolving activities offer a better understanding of the mechanisms responsible for the protective effect of DHA in the brain [25, 145]. In particular, resolvin D1 (RvD1), which originates from DHA via lipoxygenases, promotes the resolution of inflammation and has been detected in the brain [21]. Very interestingly, DHA and RvD1 promotes macrophage polarization toward a M2 state in obese mice adipose tissue associated to a decrease of pro-inflammatory cytokines and an increase of anti-inflammatory cytokines [146, 147]. In a model of LPS injection, Orr et al (2013) [129] showed that DHA exerts its anti-inflammatory effects in the brain, via its conversion into resolvins. Neuroprotectin D1 (NPD1), a DHA derived docosanoid has also been detected in the brain where it could exert anti-inflammatory and protective activities [23]. Chronic infusions of DHA or NPD1 in the brain significantly decreased neuroinflammatory processes triggered by a middle cerebral artery occlusion [139]. NPD1 even had a more potent effect than DHA [139, 148]. However, it remains to be demonstrated that NPD1 is the intermediary of the anti-inflammatory effect of DHA in the brain.

Experiments conducted in animal models have highlighted brain DHA as a potent mediator of the protective effects of dietary n-3 PUFAs. Low dietary intake of n-3 PUFA decreases DHA levels in the animal brain [149 –151]. As a result, emotional behavior (depressive-like symptoms and anxiety) as well as learning and memory are impaired as shown by others and us [152 –155]. On the other hand, positive effects of diets enriched in DHA on learning and memory have been demonstrated in laboratory animals [156 –160].

4.3 N-3 PUFAs and age-related neuroinflammation

As previously mentioned, PUFAs represent potent immunomodulatory agents. During aging, the levels and the turn-over rate of brain PUFAs decrease, particularly in the hippocampus, cortex, striatum and hypothalamus [161 –164]. Brain levels of DHA and AA diminish in aging rats with alterations in cognition and in long-term potentiation (LTP) in the hippocampus [162]. In senescence-accelerated mouse (SAMP8), a spontaneous model of accelerated aging, DHA levels decrease, whereas lipid peroxidation increases with age including that of DHA [165, 166]. In addition, the conversion of the precursors LA and ALA into their long chain derivatives becomes less efficient. The activity of the Δ6 desaturase decreases with age in the liver and the brain [167, 168]. Phospholipid synthesis pathways are also altered with age, thus reducing the incorporation of PUFAs into membranes [169]. The combination and interaction of these different alterations associated with aging contributes to a reduction in the level of DHA, i.e. a reduction in the index of membrane fluidity, in the brain of elderly people. In animals, aging was found to be associated with a decrease in the membrane content of AA in the hippocampus together with an attenuation of LTP that can be reestablished by a diet containing AA [170].

With aging, IL-6 expression is increased in the cortex of both n-3 deficient and n-3 adequate CD1 mice while IL-10 expression is decreased with no effect of long term ALA deficient or enriched diet [155]. Conversely, short-term exposure to dietary EPA reduces IL-1-induced spatial memory deficit and anxiolytic behavior [171, 172] and improves LPS and Aβ-induced inhibition of LTP in both adult and aged rats [173]. The expression of markers of microglial activation (CD68, MHCII and CD11b) increases with age in animals, as does the number of microglia in the brain of humans, attesting of the occurrence of age-related neuroinflammation [174]. Microglial cell reactivity is involved in the age-dependent increase in the production of inflammatory cytokines, as demonstrated by the inhibition of inflammatory cytokine overexpression by minocycline in aged rats [69]. In rats, the age-related activation of the microglia, production of IL-1β and alterations in hippocampal LTP are attenuated by EPA [175, 176]. Importantly, a 2-month fish-oil dietary supply increases DHA in the brain, prevents proinflammatory cytokine expression and astrocyte morphology changes in the hippocampus and restored spatial memory deficits and c-Fos-associated activation in the hippocampus of aged mice [31]. These data support the idea of the importance of DHA dietary supply in aged mammals.

To detect an anti-inflammatory action in neurodegenerative diseases, one must work with an animal model displaying an easily quantifiable inflammatory response, which is not always the case in AD models [90]. In contrast, animal model of stroke offers an easier opportunity to directly probe this mechanism of action. To visualize the effects of DHA on stroke-induced neuroinflammation, we recently used the TLR2-fluc-GFP transgenic mice exposed to either (i) a control diet; (ii) a diet depleted in n-3 polyunsaturated fatty acid (PUFA) (iii) a diet enriched in n-3 long chain PUFA (0.7 g kg⁻¹ day⁻¹, with DHA:EPA ratio of 4:1) during 3 months [20]. Real-time biophotonic/bioluminescence imaging of the TLR2 response was performed before and after middle cerebral artery occlusion (MCAO), whereas cytokines concentrations and stroke area analyses were performed 3 and 7 days after MCAO, respectively. We have observed that 3 months of DHA/EPA treatment abolished the TLR2 response after ischemic injury, while increasing the brain n-3:n-6 PUFA ratio, preventing microglial activation, reducing the ischemic lesion size and increasing concentrations of the anti-apoptotic molecule Bcl-2 in the brain [20]. Additional analysis further revealed a significant decrease in the levels of COX-2 and IL-1beta, but not other pro-inflammatory cytokines [20]. The result of this study argues for the use of n-3 long chain PUFA in preventing the initiation of TLR2-dependent signaling cascade, which lays upstream of the main pathways leading to a neuroinflammatory response.

In epidemiological and observational studies, a higher level of blood n-3 PUFAs is associated with lower proinflammatory cytokine production [177 –180]. In a cohort of elderly subjects, depressive individuals with an elevated plasma n-6:n-3 ratio were found to exhibit higher levels of TNFα and of IL-6 [180]. F2-isoprostane, a marker of oxidative stress, and telomere length, an indicator of immune cell aging, are both decreased in the blood of subjects supplemented with EPA/DHA [181]. Additionally, n-3 PUFA supplementation in elderly subjects reduced the levels of inflammatory cytokines produced by blood leukocytes stimulated in vitro [182]. The production of prostaglandin E2 by monocytes is inversely correlated to the EPA content of leukocytes obtained from aged subjects after the consumption of dietary complements containing different doses of EPA [183]. To the extent that the level of peripheral cytokines can reflect that of brain cytokines, these results would suggest that dietary n-3 PUFAs modulate neuroinflammation and associated neurobehavioral effects in elderly individuals [8] (Fig. 3).

Fig. 3

Potential role of n-3 PUFA in inflammaging. In the aged or diseased brain (AD neuropathology), microglia are primed and polarized into various phenotypes (e.g. M1 in aging) and secrete pro-inflammatory cytokines that could play a role in cognitive impairment. The protective effect of n-3 PUFAs toward cognitive deficit in aging or neurodegeneration could be linked to the promotion of an anti-inflammatory M2 phenotype.

Epidemiological studies further highlight the importance of n-3 PUFA levels in the development of age-linked neurodegenerative disorders. Indeed, decreases in plasma and brain DHA levels have been shown in patients with AD. These results, however, remain controversial, since other studies have demonstrated an increase or an absence of variation in brain DHA levels in similar populations. Nonetheless, the risk of dementia was found to be augmented in elderly subjects presenting low levels of circulating EPA [184]. In addition, regular consumption of diets rich in n-3 PUFA, such as the Mediterranean diet, appears to contribute to a decrease in the risk of depression and/or dementia in the elderly [185, 186]. Using a mouse model of AD, the Tg2576 mouse, dietary supply of DHA reduces both the formation of amyloid plaques or the accumulation of caspase-cleaved products, while protecting against the loss of synaptic markers [187 –189]. However, the administration of DHA-containing dietary supplements to patients with AD or mild cognitive impairment has not yielded conclusive results [190]. Only in vitro studies suggested a potential beneficial effect of DHA mediators. Indeed, it was shown in vitro that RvD1 promotes Aβ phagocytosis [191] and that NPD1 downregulates inflammatory signaling and amyloidogenic APP cleavage [192]. Data from preclinical and clinical studies all indicate that the effect of DHA differs according to apolipoprotein E (APOE) genotype [193 –196]. A reduced brain uptake has been suggested as a mechanism underlying the lack of benefit of DHA in APOE4 carriers [193, 197]. However, APOE4 could simply counteract any effect of DHA by its known aggravating impact on peripheral immune and inflammatory responses, including microglial activation [198, 199]. Therefore, although preclinical studies support an effect of DHA in the prevention and / or treatment of age-related diseases, further clinical trials adapted to APOE genotype remain required to determine the best approach for an optimal therapeutic effect.

5 Conclusion

Growing evidence highlight an association between inflammation in cerebral tissues and mood and cognitive disorders during infection, aging and neurodegenerative disorders. Whether neuroinflammation processes are a cause or a consequence of the underlying disease and its symptoms is still debated. However, the current state of knowledge strongly points to potential disease modification value of treating neuroinflammation in the preclinical stages of neurodegenerative diseases. More specifically, the impact of DHA, either from the diet or from dietary-supplementation, as a preventive therapeutic strategy needs to be investigated.

Footnotes

Acknowledgments

This work has been supported by FRM, Région Aquitaine, Société française de Nutrition and INRA (SL). The work of FC is supported by grants from the Canadian Institutes of Health Research (CIHR), the Alzheimer Society Canada, the Parkinson Society Canada and the Fonds de la recherche en santé du Québec (FRQ-S)

References

Dantzer

1998

Cytokines and sickness behavior

Ann N Y Acad Sci 840 586–590

Czirr

Wyss-Coray

2012

The immunology of neurodegeneration

J Clin Invest 122 1156–1163

Wilson

Finch

Cohen

2002

Cytokines and cognition-the case for a head-to-toe inflammatory paradigm

J Am Geriatr Soc 50 2041–2056

Lampron

Elali

Rivest

2013

Innate immunity in the CNS: Redefining the relationship between the CNS and Its environment

Neuron 78 214–232

Wyss-Coray

2006

Inflammation in Alzheimer disease: Driving force, bystander or beneficial response?

Nat Med 12 1005–1015

Hurley

Tizabi

2013

Neuroinflammation, neurodegeneration, and depression

Neurotox Res 23 131–144

Perry

Nicoll

Holmes

2010

Microglia in neurodegenerative disease

Nat Rev Neurol 6 193–201

Laye

2010

Polyunsaturated fatty acids, neuroinflammation and well being

Prostaglandins Leukot Essent Fatty Acids 82 295–303

Perry

Newman

Cunningham

2003

The impact of systemic infection on the progression of neurodegenerative disease

Nat Rev Neurosci 4 103–112

10.

Norden

Godbout

2013

Review: Microglia of the aged brain: Primed to be activated and resistant to regulation

Neuropathol Appl Neurobiol 39 19–34

11.

Mosher

Wyss-Coray

2014

Microglial dysfunction in brain aging and Alzheimer's disease

Biocem Pharmacol 88 594–604

12.

Capuron

2011

Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: Role in neuropsychiatric symptoms

Biol Psychiatry 70 175–182

13.

Capuron

2009

Vitamin E status and quality of life in the elderly: Influence of inflammatory processes

Br J Nutr 102 1390–1394

14.

Kreisl

2013

A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation

J Cereb Blood Flow Metab 33 53–58

15.

Bettcher

2012

C-reactive protein is related to memory and medial temporal brain volume in older adults

Brain Behav Immun 26 103–108

16.

Plourde

Cunnane

2007

Extremely limited synthesis of long chain polyunsaturates in adults: Implications for their dietary essentiality and use as supplements

Appl Physiol Nutr Metab 32 619–634

17.

Mizota

2009

Effect of dietary fatty acid composition on Th1/Th2 polarization in lymphocytes

JPEN J Parenter Enteral Nutr 33 390–396

18.

Gopinath

Yelliboina

Singh

Prasad

2013

Impact of supplementing preoperative intravenous omega 3 Fatty acids in fish oil on immunomodulation in elderly patients undergoing hip surgery

Indian J Surg 75 478–484

19.

Sierra

Lara-Villoslada

Comalada

Olivares

Xaus

2006

Dietary fish oil n-3 fatty acids increase regulatory cytokine production and exert anti-inflammatory effects in two murine models of inflammation

Lipids 41 1115–1125

20.

Lalancette-Hebert

2011

Accumulation of dietary docosahexaenoic acid in the brain attenuates acute immune response and development of postischemic neuronal damage

Stroke 42 2903–2909

21.

Hong

2007

Resolvin D1, protectin D1, and related docosahexaenoic acid-derived products: Analysis via electrospray/low energy tandem mass spectrometry based on spectra and fragmentation mechanisms

J Am Soc Mass Spectrom 18 128–144

22.

Hong

2013

Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: Targeting novel lipid mediator pathways in mitigation of acute kidney injury

Front Immunol 4 13

23.

Bazan

2009

Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease

J Lipid Res 50 Suppl S400–S405

24.

Bazan

Calandria

Serhan

2010

Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1

J Lipid Res 51 2018–2031

25.

Bannenberg

Serhan

1801

Specialized pro-resolving lipid mediators in the inflammatory response: An update

Biochim Biophys Acta 1260–1273

26.

Dalli

2013

Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents

Chem Biol 20 188–201

27.

Calder

2008

Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases

Mol Nutr Food Res 52 885–897

28.

Calder

2013

Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology?

Br J Clin Pharmacol 75 645–662

29.

Bowen

Clandinin

2005

Maternal dietary 6n-3 is more effective than 3n-3 in increasing the 6n-3 content in phospholipids of glial cells from neonatal rat brain

Br J Nutr 93 601–611

30.

Destaillats

2010

Differential effect of maternal diet supplementation with alpha-Linolenic adcid or n-3 long-chain polyunsaturated fatty acids on glial cell phosphatidylethanolamine and phosphatidylserine fatty acid profile in neonate rat brains

Nutr Metab (Lond) 7 2

31.

Labrousse

2012

Short-term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice

PLoS Onee 7 36861

32.

Simopoulos

2001

n-3 fatty acids and human health: Defining strategies for public policy

Lipids 36 Suppl S83–S99

33.

Simopoulos

2011

Evolutionary aspects of diet: The omega-6/omega-3 ratio and the brain

Mol Neurobiol 44 203–215

34.

Glass

Saijo

Winner

Marchetto

Gage

2010

Mechanisms underlying inflammation in neurodegeneration

Cell 140 918–934

35.

Town

Nikolic

Tan

2005

The microglial “activation” continuum: From innate to adaptive responses

J Neuroinflammation 2 24

36.

Biber

Neumann

Inoue

Boddeke

2007

Neuronal ‘On’ and ‘Off’ signals control microglia

Trends Neurosci 30 596–602

37.

Alliot

Godin

Pessac

1999

Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain

Brain Res Dev Brain Res 117 145–152

38.

Herbomel

Thisse

2001

Zebrafish early macrophages colonize cephalic mesenchyme and developing brain, retina, and epidermis through a M-CSF receptor-dependent invasive process

Dev Biol 238 274–88

39.

Ginhoux

2010

Fate mapping analysis reveals that adult microglia derive from primitive macrophages

Science 330 841–845

40.

Kierdorf

Katzmarski

Haas

Prinz

2013

Bone marrow cell recruitment to the brain in the absence of irradiation or parabiosis bias

PLoS Onee 8 58544

41.

Saijo

Glass

2011

Microglial cell origin and phenotypes in health and disease

Nat Rev Immunol 11 775–787

42.

Prinz

Priller

2014

Microglia and brain macrophages in the molecular age: From origin to neuropsychiatric disease

Nat Rev Neurosci 15 300–312

43.

Rezaie

Male

2002

Mesoglia & microglia–a historical review of the concept of mononuclear phagocytes within the central nervous system

J Hist Neurosci 11 325–374

44.

Schulz

2012

A lineage of myeloid cells independent of Myb and hematopoietic stem cells

Science 336 86–90

45.

Gautier

2012

Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages

Nat Immunol 13 1118–1128

46.

Butovsky

2014

Identification of a unique TGF-beta-dependent molecular and functional signature in microglia

Nat Neurosci 17 131–143

47.

Hanisch

Kettenmann

2007

Microglia: Active sensor and versatile effector cells in the normal and pathologic brain

Nat Neurosci 10 1387–1394

48.

Neumann

2008

Microglia cells protect neurons by direct engulfment of invading neutrophil granulocytes: A new mechanism of CNS immune privilege

J Neurosci 28 5965–5975

49.

Neher

2011

Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death

J Immunol 186 4973–4983

50.

McArthur

2010

Annexin A A central player in the anti-inflammatory and neuroprotective role of microglia

J Immunol 185 6317–6328

51.

Brown

Neher

2014

Microglial phagocytosis of live neurons

Nat Rev Neurosci 15 209–216

52.

Beutler

2004

Inferences, questions and possibilities in Toll-like receptor signalling

Nature 430 257–263

53.

Mariathasan

Monack

2007

Inflammasome adaptors and sensors: Intracellular regulators of infection and inflammation

Nat Rev Immunol 7 31–40

54.

Drouin-Ouellet

Cicchetti

2012

Inflammation and neurodegeneration: The story ‘retolled’

Trends Pharmacol Sci 33 542–551

55.

Zhang

Mosser

2008

Macrophage activation by endogenous danger signals

J Pathol 214 161–178

56.

Dantzer

O'Connor

Freund

Johnson

Kelley

2008

From inflammation to sickness and depression: When the immune system subjugates the brain

Nat Rev Neurosci 9 46–56

57.

Lalancette-Hebert

Gowing

Simard

Weng

Kriz

2007

Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain

J Neurosci 27 2596–2605

58.

Ransohoff

Perry

2009

Microglial physiology: Unique stimuli, specialized responses

Annu Rev Immunol 27 119–145

59.

Cherry

Olschowka

O'Banion

2014

Are “resting” microglia more “m2”? Front Immunol

5 594

60.

David

Kroner

2011

Repertoire of microglial and macrophage responses after spinal cord injury

Nat Rev Neurosci 12 388–399

61.

Zhan

2014

Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior

Nat Neurosci 17 400–406

62.

Neumann

2001

Control of glial immune function by neurons

Glia 36 191–199

63.

Streit

2006

Microglial senescence: Does the brain's immune system have an expiration date?

Trends Neurosci 29 506–510

64.

Cox

Carney

Miller

Lynch

2012

CD200 fusion protein decreases microglial activation in the hippocampus of aged rats

Brain Behav Immun 26 789–796

65.

Streit

Xue

2014

Human CNS immune senescence and neurodegeneration

Curr Opin Immunol 29C 93–96

66.

Franceschi

2000

Inflamm-aging. An evolutionary perspective on immunosenescence

Ann N Y Acad Sci 908 244–254

67.

Dilger

Johnson

2008

Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system

J Leukoc Biol 84 932–939

68.

Tremblay

2011

The role of microglia in the healthy brain

J Neurosci 31 16064–1609

69.

Griffin

2006

The age-related attenuation in long-term potentiation is associated with microglial activation

J Neurochem 99 1263–1272

70.

Hickman

2013

The microglial sensome revealed by direct RNA sequencing

Nat Neurosci 16 1896–1905

71.

Heneka

O'Banion

Terwel

Kummer

2010

Neuroinflammatory processes in Alzheimer's disease

J Neural Transm 117 919–947

72.

Wyss-Coray

Rogers

2012

Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature

Cold Spring Harb Perspect Meda 2 006346

73.

Perry

Holmes

2014

Microglial priming in neurodegenerative disease

Nat Rev Neurol 10 217–224

74.

Perry

Cunningham

Holmes

2007

Systemic infections and inflammation affect chronic neurodegeneration

Nat Rev Immunol 7 161–167

75.

Cunningham

Wilcockson

Campion

Lunnon

Perry

2005

Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration

J Neurosci 25 9275–9284

76.

Norden

Muccigrosso

Godbout

2014

Microglial Priming and Enhanced Reactivity to Secondary Insult in Aging, and Traumatic CNS injury, and Neurodegenerative Disease

Neuropharmacology 10.028, Epub ahead of print

77.

Cunningham

2009

Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease

Biol Psychiatry 65 304–312

78.

Field

Campion

Warren

Murray

Cunningham

2010

Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration

Brain Behav Immun 24 996–1007

79.

Cunningham

2013

Microglia and neurodegeneration: The role of systemic inflammation

Glia 61 71–90

80.

Ray

2007

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

Nat Med 13 1359–1362

81.

Galimberti

2008

Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration

J Neurol 255 539–544(2008)

82.

Bennett

2012

Plasma levels of complement 4a protein are increased in Alzheimer's disease

Alzheimer Dis Assoc Disord 26 329–334

83.

Thambisetty

2011

Plasma biomarkers of brain atrophy in Alzheimer's disease

PLoS Onee 6 28527

84.

Sokolova

2009

Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease

Brain Pathol 19 392–398

85.

Edison

2008

Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK1115-PET and [11C]PIB-PET study

Neurobiol Dis 32 412–419

86.

int’ Veld

2001

Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease

N Engl J Med 345 1515–1521

87.

McGeer

Rogers

McGeer

2006

Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years

J Alzheimers Dis 9 271–276

88.

Schwab

Klegeris

McGeer

1802

Inflammation in transgenic mouse models of neurodegenerative disorders

Biochim Biophys Acta 889–902

89.

Akiyama

2000

Inflammation and Alzheimer's disease

Neurobiol Aging 21 383–421

90.

Quinn

2003

Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease

J Neuroimmunol 137 32–41

91.

Janelsins

2005

Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice

J Neuroinflammation 2 23

92.

Kitazawa

Oddo

Yamasaki

Green

LaFerla

2005

Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease

J Neurosci 25 8843–8853

93.

Poisnel

2012

PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition

Neurobiol Aging 33 2561–2571

94.

Ferretti

Bruno

Ducatenzeiler

Klein

Cuello

2012

Intracellular Abeta-oligomers and early inflammation in a model of Alzheimer's disease

Neurobiol Aging 33 1329–1342

95.

Boissonneault

2009

Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease

Brain 132 1078–1092

96.

Michaud

2013

Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology

Proc Natl Acad Sci U S A 110 1941–1946

97.

Yang

Y-M

Shang

D-S

Zhao

W-D

Fang

W-G

Chen

Y-H

2013

Microglial TNF-α-Dependent Elevation of MHC Class I Expression on Brain Endothelium Induced by Amyloid-Beta Promotes T Cell Transendothelial Migration

Neurochemical research 38 2295–2304

98.

Lee

2010

TGF-beta induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid beta plaques in Alzheimer's disease

Cell Death Dise 1 110

99.

Giuliani

Vernay

Leuba

Schenk

2009

Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-alpha metabolism

Brain Res Bull 80 302–308

100.

McAlpine

2009

Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology

Neurobiol Dis 34 163–177

101.

Chakrabarty

2012

Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition

Mol Neurodegener 7 36

102.

Krabbe

2013

Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology

PLoS Onee 8 60921

103.

Rivest

2009

Regulation of innate immune responses in the brain

Nat Rev Immunol 9 429–439

104.

Rothwell

Luheshi

2000Trends Neurosci 23 618–625Interleukin 1 in the braBiology, pathology and therapeutic target

105.

Griffin

Sheng

Roberts

Mrak

1995

Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution

J Neuropathol Exp Neurol 54 276–281

106.

Apelt

Schliebs

2001

Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tgmice with Alzheimer plaque pathology

Brain Res 894 21–30

107.

Ghosh

2013

Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model

J Neurosci 33 5053–5064

108.

Cho

2011

CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease

J Biol Chem 286 32713–32722

109.

St-Amour

2014

IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Abeta pathology

J Neuroinflammation 11 54

110.

Liu

Condello

Schain

Harb

Grutzendler

2010

CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-beta phagocytosis

J Neurosci 30 17091–17101

111.

Lee

2010

CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models

Am J Pathol 177 2549–2562

112.

Fuhrmann

2010

Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease

Nat Neurosci 13 411–413

113.

Bhaskar

2010

Regulation of tau pathology by the microglial fractalkine receptor

Neuron 68 19–31

114.

Hoozemans

Rozemuller

van Haastert

Eikelenboom

van Gool

2011

Neuroinflammation in Alzheimer's disease wanes with age

J Neuroinflammation 8 171

115.

Querfurth

LaFerla

2010

Alzheimer's disease

N Engl J Med 362 329–344

116.

Aisen

2000

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study

Neurology 54 588–593

117.

Breitner

1995

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs

Neurobiol Aging 16 523–530

118.

von Bernhardi

2010

Immunotherapy in Alzheimer's disease: Where do we stand? Where should we go?

J Alzheimers Dis 19 405–421

119.

Butchart

Holmes

2012

Systemic and central immunity in Alzheimer's disease: Therapeutic implications

CNS Neurosci Ther 18 64–76

120.

Cummings

2007

Treatment of Alzheimer's disease: The role of symptomatic agents in an era of disease-modifying therapies

Rev Neurol Dis 4 57–62

121.

Meinert

McCaffrey

Breitner

2009

Alzheimer's Disease Anti-inflammatory Prevention Trial: Design, methods, and baseline results

Alzheimers Dement 5 93–104

122.

Breitner

2011

Extended results of the Alzheimer's disease anti-inflammatory prevention trial

Alzheimers Dement 7 402–411

123.

Group A. D. A. P. T. R. 2013

Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)

Alzheimers Dement 9 714–723

124.

Cunnane

1994

Antioxidants, free radicals and PUFA

Prostaglandins Leukot Essent Fatty Acids 50 363–364

125.

Simopoulos

2006

Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: Nutritional implications for chronic diseases

Biomed Pharmacother 60 502–507

126.

Bang

Dyerberg

Sinclair

1980

The composition of the Eskimo food in north western Greenland

Am J Clin Nutr 33 2657–2661

127.

Kromann

Green

1980

Epidemiological studies in the Upernavik district, Greenland

Incidence of some chronic diseases -Acta Med Scand 208 401–406

128.

Schaebel

Vestergaard

Laurberg

Rathcke

Andersen

2013

Intake of traditional Inuit diet vary in parallel with inflammation as estimated from YKL-40 and hsCRP in Inuit and non-Inuit in Greenland

Atherosclerosis 228 496–501

129.

Orr

Trepanier

Bazinet

2013

n-3 Polyunsaturated fatty acids in animal models with neuroinflammation

Prostaglandins Leukot Essent Fatty Acids 88 97–103

130.

Jump

2002

Dietary polyunsaturated fatty acids and regulation of gene transcription

Curr Opin Lipidol 13 155–164

131.

Calder

2005

Polyunsaturated fatty acids and inflammation

Biochem Soc Trans 33 423–427

132.

Chapkin

Kim

Lupton

McMurray

2009

Dietary docosahexaenoic and eicosapentaenoic acid: Emerging mediators of inflammation

Prostaglandins Leukot Essent Fatty Acids 81 187–191

133.

Willis

Shukitt-Hale

Joseph

2009

Modulation of cognition and behavior in aged animals: Role for antioxidant- and essential fatty acid-rich plant foods

Am J Clin Nutr 89 1602S–1606S

134.

Willis

Shukitt-Hale

Cheng

Joseph

2009

Dose-dependent effects of walnuts on motor and cognitive function in aged rats

Br J Nutr 101 1140–1144

135.

Carey

Fisher DR Joseph

Shukitt-Hale

2013

The ability of walnut extract and fatty acids to protect against the deleterious effects of oxidative stress and inflammation in hippocampal cells

Nutr Neurosci 16 13–20

136.

Poulose

Bielinski

Shukitt-Hale

2013

Walnut diet reduces accumulation of polyubiquitinated proteins and inflammation in the brain of aged rats

J Nutr Biochem 24 912–919

137.

De Smedt-Peyrusse

2008

Docosahexaenoic acid prevents lipopolysaccharide-induced cytokine production in microglial cells by inhibiting lipopolysaccharide receptor presentation but not its membrane subdomain localization

J Neurochem 105 296–307

138.

Mingam

2008

Uncoupling of interleukin-6 from its signalling pathway by dietary n-3-polyunsaturated fatty acid deprivation alters sickness behaviour in mice

Eur J Neurosci 28 1877–1886

139.

Marcheselli

2003

Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression

J Biol Chem 278 43807–43817

140.

Huang

2007

A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury

Brain 130 3004–3019

141.

Julien

2010

High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model

Neurobiol Aging 31 1516–1531

142.

McNamara

2010

Omega-3 fatty acid deficiency increases constitutive pro-inflammatory cytokine production in rats: Relationship with central serotonin turnover

Prostaglandins Leukot Essent Fatty Acids 83 185–191

143.

Curtis

2000

n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation

J Biol Chem 275 721–724

144.

Michael-Titus

2007

Omega-3 fatty acids and neurological injury

Prostaglandins Leukot Essent Fatty Acids 77 295–300

145.

Serhan

Chiang

Van Dyke

2008

Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators

Nat Rev Immunol 8 349–361

146.

Claria

Gonzalez-Periz

Lopez-Vicario

Rius

Titos

2011

New insights into the role of macrophages in adipose tissue inflammation and Fatty liver disease: Modulation by endogenous omega-3 Fatty Acid-derived lipid mediators

Front Immunol 2 49

147.

Titos

2011

Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype

J Immunol 187 5408–5418

148.

Lukiw

Bazan

2008

Docosahexaenoic acid and the aging brain

J Nutr 138 2510–2514

149.

Calder

2007

Immunomodulation by omega-3 fatty acids

Prostaglandins Leukot Essent Fatty Acids 77 327–335

150.

Carrie

Guesnet

Bourre

Frances

2000

Diets containing long-chain n-3 polyunsaturated fatty acids affect behaviour differently during development than ageing in mice

Br J Nutr 83 439–447

151.

Connor

Neuringer

Lin

1990

Dietary effects on brain fatty acid composition: The reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys

J Lipid Res 31 237–247

152.

Fedorova

Salem

2006

Omega-3 fatty acids and rodent behavior

Prostaglandins Leukot Essent Fatty Acids 75 271–289

153.

Lafourcade

2011

Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions

Nat Neurosci 14 345–350

154.

Larrieu

Madore

Joffre

Laye

2012

Nutritional n-3 polyunsaturated fatty acids deficiency alters cannabinoid receptor signaling pathway in the brain and associated anxiety-like behavior in mice

J Physiol Biochem 68 671–681

155.

Moranis

2012

Long term adequate n-3 polyunsaturated fatty acid diet protects from depressive-like behavior but not from working memory disruption and brain cytokine expression in aged mice

Brain Behav Immun 26 721–731

156.

Gamoh

Hashimoto

Hossain

Masumura

2001

Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats

Clin Exp Pharmacol Physiol 28 266–270

157.

Carrie

2002

Docosahexaenoic acid-rich phospholipid supplementation: Effect on behavior, learning ability, and retinal function in control and n-3 polyunsaturated fatty acid deficient old mice

Nutr Neurosci 5 43–52

158.

Gamoh

1999

Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats

Neuroscience 93 237–241

159.

Yehuda

Rabinovitz

Mostofsky

1999

Treatment with a polyunsaturated fatty acid prevents deleterious effects of Ro4-Eur J Pharmacol

365 27–34

160.

Arsenault

Julien

Tremblay

Calon

2011

DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice

PLoS Onee 6 17397

161.

Lopez

Ilincheta de Boschero

Castagnet

Giusto

1995

Age-associated changes in the content and fatty acid composition of brain glycerophospholipids

Comp Biochem Physiol B Biochem Mol Biol 112 331–343

162.

Favreliere

2003

DHA-enriched phospholipid diets modulate age-related alterations in rat hippocampus

Neurobiol Aging 24 233–243

163.

Little

Lynch

Manku

Nicolaou

2007

Docosahexaenoic acid-induced changes in phospholipids in cortex of young and aged rats: A lipidomic analysis

Prostaglandins Leukot Essent Fatty Acids 77 155–162

164.

McNamara

Liu

Jandacek

Rider

Tso

2008

The aging human orbitofrontal cortex: Decreasing polyunsaturated fatty acid composition and associated increases in lipogenic gene expression and stearoyl-CoA desaturase activity

Prostaglandins Leukot Essent Fatty Acids 78 293–304

165.

Petursdottir

Farr

Morley

Banks

Skuladottir

2007

Lipid peroxidation in brain during aging in the senescence-accelerated mouse (SAM)

Neurobiol Aging 28 1170–1178

166.

Petursdottir

Farr

Morley

Banks

Skuladottir

2008

Effect of dietary n-3 polyunsaturated fatty acids on brain lipid fatty acid composition, learning ability, and memory of senescence-accelerated mouse

J Gerontol A Biol Sci Med Sci 63 1153–1160

167.

Bourre

Piciotti

1992

Delta-6 desaturation of alpha-linolenic acid in brain and liver during development and aging in the mouse

Neurosci Lett 141 65–68

168.

Kumar

1999

Changes in membrane fatty acids and delta-9 desaturase in senescence accelerated (SAMP8) mouse hippocampus with aging

Life Sci 65 1657–1662

169.

Ilincheta de Boschero

Roque

Salvador

Giusto

2000

Alternative pathways for phospholipid synthesis in different brain areas during aging

Exp Gerontol 35 653–668

170.

McGahon

Martin

Horrobin

Lynch

1999

Age-related changes in synaptic function: Analysis of the effect of dietary supplementation with omega-3 fatty acids

Neuroscience 94 305–314

171.

Song

Leonard

Horrobin

2004

Dietary ethyl-eicosapentaenoic acid but not soybean oil reverses central interleukin-1-induced changes in behavior, corticosterone and immune response in rats

Stress 7 43–54

172.

Song

Manku

Horrobin

2008

Long-chain polyunsaturated fatty acids modulate interleukin-1beta-induced changes in behavior, monoaminergic neurotransmitters, and brain inflammation in rats

J Nutr 138 954–963

173.

Minogue

Lynch

Loane

Herron

Lynch

2007

Modulation of amyloid-beta-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid

J Neurochem 103 914–926

174.

Godbout

2005

Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system

FASEB J 19 1329–1331

175.

Lynch

2007

Eicosapentaenoic acid confers neuroprotection in the amyloid-beta challenged aged hippocampus

Neurobiol Aging 28 845–855

176.

Martin

Spencer

Horrobin

Lynch

2002

Long-term potentiation in aged rats is restored when the age-related decrease in polyunsaturated fatty acid concentration is reversed

Prostaglandins Leukot Essent Fatty Acids 67 121–130

177.

Farzaneh-Far

Harris

Garg

Whooley

2009

Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study

Atherosclerosis 205 538–543

178.

Ferrucci

2006

Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers

J Clin Endocrinol Metab 91 439–446

179.

Kalogeropoulos

2010

Unsaturated fatty acids are inversely associated and n-6/n-3 ratios are positively related to inflammation and coagulation markers in plasma of apparently healthy adults

Clin Chim Acta 411 584–591

180.

Kiecolt-Glaser

2007

Depressive symptoms, omega-omega-3 fatty acids, and inflammation in older adults

Psychosom Med 69 217–224

181.

Kiecolt-Glaser

2013

Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial

Brain Behav Immun 28 16–24

182.

Meydani

1994

Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: Comparison between young and older women

J Nutr 1 121 547–555

183.

Rees

2006

Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: A comparison of young and older men

Am J Clin Nutr 83 331–342

184.

Samieri

2011

omega-3 fatty acids and cognitive decline: Modulation by ApoEepsilon4 allele and depression

Neurobiol Aging 32 2317 e13-2317.e22.

185.

Feart

2008

Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: Data from the Bordeaux sample of the Three-City Study

Am J Clin Nutr 87 1156–1162

186.

Feart

2011

Adherence to a Mediterranean diet and plasma fatty acids: Data from the Bordeaux sample of the Three-City study

Br J Nutr 106 149–158

187.

Lim

2005

A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model

J Neurosci 25 3032–3040

188.

Calon

2004

Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model

Neuron 43 633–645

189.

Calon

2005

Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease

Eur J Neurosci 22 617–626

190.

Calon

Cole

2007

Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: Evidence from animal studies

Prostaglandins Leukot Essent Fatty Acids 77 287–293

191.

Mizwicki

2013

1alpha, 25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-beta phagocytosis and inflammation in Alzheimer's disease patients

J Alzheimers Dis 34 155–170

192.

Zhao

2011

Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARgamma-mediated mechanisms in Alzheimer's disease models

PLoS Onee 6 15816

193.

Salem

Vandal

Calon

2015

The benefit of docosahexaenoic acid for the adult brain in aging and dementia

Prostaglandins Leukot Essent Fatty Acids 92 15–22

194.

Frautschy

Cole

2011

What was lost in translation in the DHA trial is whom you should intend to treat

Alzheimers Res Ther 3 2

195.

Quinn

2010

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial

JAMA 304 1903–1911

196.

Barberger-Gateau

Samieri

Feart

Plourde

2011

Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: Interaction with apolipoprotein E genotype

Curr Alzheimer Res 8 479–491

197.

Vandal

2014

Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2

J Neurochem 129 516–526

198.

Egensperger

Kosel

von Eitzen

Graeber

1998

Microglial activation in Alzheimer disease: Association with APOE genotype

Brain Pathol 8 439–447

199.

Montine

Keene

Montine

2015

Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia

FASEB J 14-262683Epub ahead of print

N-3 polyunsaturated fatty acid and neuroinflammation in aging and Alzheimer's disease

Abstract

Keywords

1 Introduction

2 The brain innate immune system (BIIS)

3.1 Neuroinflammation, the aged brain and Alzheimer's disease

4 Polyunsaturated fatty acids and neuroinflammation

4.1 N-3 PUFAs: A brief overview

4.3 N-3 PUFAs and age-related neuroinflammation

Footnotes

Acknowledgments

References